Technology
Health
Pharmaceutical

Novus Therapeutics

$4.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (2.52%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NVUS and other stocks, options, ETFs, and crypto commission-free!

About

Novus Therapeutics, Inc. Common Stock, also called Novus Therapeutics, is a pharmaceutical company, which engages in the acquisition, development, and commercialization of ear, nose, and throat products. Read More The firm's lead product, OP-02, is a surfactant-based, combination drug product being developed as a potential treatment option for patients at risk for or with otitis media, which is often caused by Eustachian tube dysfunction. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Employees
7
Headquarters
Irvine, California
Founded
2004
Market Cap
37.41M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
62.73K
High Today
$4.15
Low Today
$3.91
Open Price
$4.03
Volume
2.69K
52 Week High
$8.61
52 Week Low
$1.52

Collections

Technology
Health
Pharmaceutical
Therapy
Media
2014 IPO
US
North America

Earnings

-$2.70
-$1.80
-$0.90
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.